Corbus Pharmaceuticals’ (CRBP) Outperform Rating Reaffirmed at Mizuho

Mizuho reiterated their outperform rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP) in a research report sent to investors on Friday morning, Benzinga reports. Mizuho currently has a $74.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a buy rating and issued a $80.00 target price on shares of Corbus Pharmaceuticals in a research report on Tuesday, August 6th. Royal Bank of Canada restated an outperform rating and set a $82.00 price objective on shares of Corbus Pharmaceuticals in a research report on Friday. Wedbush lowered their target price on Corbus Pharmaceuticals from $85.00 to $51.00 and set an outperform rating on the stock in a research note on Friday. Lifesci Capital raised shares of Corbus Pharmaceuticals to a strong-buy rating in a research report on Wednesday, August 21st. Finally, StockNews.com downgraded shares of Corbus Pharmaceuticals from a hold rating to a sell rating in a research report on Saturday, August 10th. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Corbus Pharmaceuticals presently has a consensus rating of Moderate Buy and a consensus price target of $65.86.

Corbus Pharmaceuticals Trading Down 2.7 %

Shares of Corbus Pharmaceuticals stock opened at $18.99 on Friday. Corbus Pharmaceuticals has a 52 week low of $3.03 and a 52 week high of $61.90. The company’s 50-day moving average price is $54.22 and its two-hundred day moving average price is $46.96. The stock has a market cap of $202.95 million, a PE ratio of -2.73 and a beta of 2.56.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.29. On average, equities analysts predict that Corbus Pharmaceuticals will post -3.77 EPS for the current fiscal year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several institutional investors have recently made changes to their positions in CRBP. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Corbus Pharmaceuticals in the first quarter valued at approximately $976,000. Vanguard Group Inc. lifted its stake in shares of Corbus Pharmaceuticals by 143.7% in the 1st quarter. Vanguard Group Inc. now owns 437,264 shares of the biopharmaceutical company’s stock valued at $17,158,000 after purchasing an additional 257,808 shares during the last quarter. Altitude Crest Partners Inc. acquired a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at $4,069,000. Price T Rowe Associates Inc. MD bought a new stake in Corbus Pharmaceuticals in the first quarter worth $7,554,000. Finally, Janus Henderson Group PLC acquired a new position in Corbus Pharmaceuticals during the first quarter worth $13,363,000. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.